Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ceftaroline: A Success for Biomarker Development

This article was originally published in RPM Report

Executive Summary

The regulatory environment for anti-infective approvals is getting better: that is one message from the positive FDA advisory committee review of Forest’s ceftaroline. A corollary message is that the work on biomarkers and improved endpoints (by groups outside FDA) is having an impact.

You may also be interested in...



Optimer Dificid FDA Approval for C. Diff Hinges on How to Describe Lasting Effect

Optimer’s Dificid (fidaxomicin) oral tablets for C. difficile received a strong endorsement from the Food & Drug Administration’s Anti-Infective Drugs Advisory Committee on April 5. Final approval of Optimer’s application awaits resolution of labeling language regarding the drug’s ability to deter recurrence of C. difficile infections. The drug has an initial (priority review) PDUFA date of May 30.

Forest Labs Had Effective "Co-Sponsor" for Ceftaroline Review

FDA got a chance to show off its ability to stimulate antibiotic development during an advisory committee review of a new cephalosporin from Forest Labs. In the past, the agency has been faulted for failing to set clear targets for anti-infective trials; with ceftaroline, the agency went to the other extreme, stepping in to support an application with key re-analyses of data.

Antibiotic Early Endpoints: FDA Looking At Patient Observations

An effort to identify early biomarkers of antibiotic efficacy is turning toward patient assessments of drug activity. FDA and industry scientists are both participating in the biomarker effort. The attention to patient observations reflects a growing interest at FDA.

Topics

UsernamePublicRestriction

Register

OM006051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel